Statin naive patients during acute coronary syndrome in Malaysia

Chua, N.Y.C.; Chong, P.F.; Khir, R. Najme; Lim, C.W.; Ismail, J.R.; Arshad, Mohd Fadzil; Ibrahim, Zulkifilie; Kasim, Sazzli

doi:10.1016/j.atherosclerosis.2017.06.591

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding lipid profile, the study reported lower level of cholesterol and triglyceride, VLDL,LDL, and higher level of HDL in patients on statins therapy as compared to non-statins using patients which is consistent with the lipid lowering effect of statins in a previous study . (13) By evaluating the atherogenic index (AI), the study showed lower level of AI in patients with ACS on statins therapy as compared to both nonstatins using patients and controls, this is in agreement with a previous studies that displayed a significant reduction of AI after statins therapy. (14) Concerning cardiac risk ratio (CRR) the results revealed that there was a lower CRR in patients on statins therapy as compared to both non-statins using patients and controls.…”

Section: Discussionsupporting

confidence: 90%

Differential Effects of Statins on Annexin A1 Serum Level in Patients With Acute Coronary Syndrome: A Pleiotropic Update

Sami¹,

Al-Kuraishy²,

Al-Gareeb³

2021

ATMPH

View full text Add to dashboard Cite

Uncontrolled inflammatory response is considered as an important triggering factor in the pathogenesis of atherosclerosis in patients with acute coronary syndrome (ACS), and numerous studies demonstrating the protective effect of statins therapy via its anti-inflammatory action.The aim of the present study is to estimate the protective role of statins on Annexin A1 in patients with ACS. A total number of 63 patients with ACS were recruited compared with 25 healthy control subjects . The enrollments were divided into; Group (A): Patients with ACS on atorvastatin (n=20), Group (B): Patients with ACS on rosuvastatin (n=20), Group(C): Patients with ACS were not on statins therapy (n=23), and Group(D): Healthy controls (n=25).Body mass index(BMI ) and both systolic (SBP)and diastolic blood pressures (DBP) were measured. Lipid profile, atherogenic index (AI), cardiac risk ratio (CRR), cardiovascular risk index(CVRI) and human AnxA1 level were estimated.There was significant dyslipidemic status in patients with ACS not on statins therapy as compared to patients with ACS on statins therapy and healthy controls. TC, TG, VLDL, LDL, AI, CRR and CVRI were higher in patients with ACS not on statins therapy. Higher AnxA1 levels (3.35±0.84) was obtained from patients on statins therapy as compared with controls (1.51±0.91) and non-statins using patients (2.08±0.76), (P=0.0001). AnxA1was significantly higher in rosuvastatin (3.69±0.92) than in atorvastatin (3.00±0.60)(P=0.008).AnxA1 serum level is higher in patients with ACS as compared with healthy controls. Patients with ACS on statins therapy mainly rosuvastatin showed higher level of AnxA1 compared with patients with ACS on atorvastatin.

show abstract

Section: Discussionsupporting

confidence: 90%